Table 2.
Effect of Nebulization on Four pH-Adjusted 12.5 mg/mL CFI Formulations*
| Mean vesicle size (nm) [SD] | Encapsulation (%) | Aerosol particle size distribution | ||||
|---|---|---|---|---|---|---|
| Formulation | Prior to nebulization | Collected aerosol | Prior to nebulization | Collected aerosol | VMD (μm) | GSD |
| pH 5.9 | 98.4 [35.5] | 109.4 [52.9] | 82.6 | 78.9 | 3.63 | 1.65 |
| pH 5.3 | 101.5 [29.7] | 110.2 [46.1] | 82.1 | 75.7 | 3.80 | 1.72 |
| pH 4.9 | 102.9 [35.5] | 108.2 [47.5] | 84.9 | 76.8 | 3.88 | 1.71 |
| pH 4.6 | 103.8 [39.2] | 105.9 [45.5] | 83.3 | 59.6 | 3.95 | 1.66 |
*
Formulations contain 90 mg/mL sucrose and 0.1% polysorbate. Vesicle size data are reported as mean (in nm) and [SD]. The state of ciprofloxacin encapsulation is reported in terms of percentage and represents single measurements. The aerosol particle size distribution is reported in terms of the Volume Mean Diameter (VMD) and Geometric Standard Deviation (GSD). SD, standard deviation.